Mareike K Körber1, Elisabeth Langer2,3, Lutz Kaufner1, Michael Sander4, Christian Von Heymann1,5. 1. Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin Germany. 2. Labor Berlin - Charite Vivantes GmbH, Berlin Germany. 3. Institute for Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin Germany. 4. Department of Anaesthesiology and Intensive Care Medicine, Universitätsklinikum Giessen-Marburg Germany. 5. Department of Anaesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Therapy, "Vivantes Netzwerk für Gesundheit GmbH Klinikum im Friedrichshain", Berlin, Germany.
Abstract
BACKGROUND: A bleeding patient undergoing therapy with new oral anticoagulants is every clinician's nightmare as no specific reversal agent is available yet. This in vitro study investigated the effect of prothrombin complex concentrate (PCC), recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (aPCC) on supratherapeutic rivaroxaban concentrations using standard laboratory parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT] and PT ratio) and thromboelastometry (clotting time [CT]). MATERIALS AND METHODS: Blood samples from 10 healthy volunteers were collected and spiked with a supratherapeutic dose of rivaroxaban. Afterwards PCC, rFVIIa and aPCC were added in two doses. The laboratory parameters were measured and thromboelastometry was performed. RESULTS: The addition of the reversal agents had the following statistically significant effects (all p<0.01): +25 IU/kg PCC: CT -15 s, aPTT +5 s; +50 IU/kg PCC: aPTT +11 s; +90 μg rFVIIa: CT -141 s; +25 IU/kg aPCC: CT -142 s, aPTT -9 s, PT ratio +14%, PT -10.5 s; +50 IU/kg aPCC: CT -118 s, aPTT -7 s, PT ratio +17%, PT -12.2 s. DISCUSSION: rFVIIa and aPCC, but not PCC, appear to shorten coagulation times significantly in standard laboratory and thromboelastometry assays. These results need confirmation through evaluation of these agents in the clinical setting.
BACKGROUND: A bleedingpatient undergoing therapy with new oral anticoagulants is every clinician's nightmare as no specific reversal agent is available yet. This in vitro study investigated the effect of prothrombin complex concentrate (PCC), recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (aPCC) on supratherapeutic rivaroxaban concentrations using standard laboratory parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT] and PT ratio) and thromboelastometry (clotting time [CT]). MATERIALS AND METHODS: Blood samples from 10 healthy volunteers were collected and spiked with a supratherapeutic dose of rivaroxaban. Afterwards PCC, rFVIIa and aPCC were added in two doses. The laboratory parameters were measured and thromboelastometry was performed. RESULTS: The addition of the reversal agents had the following statistically significant effects (all p<0.01): +25 IU/kg PCC: CT -15 s, aPTT +5 s; +50 IU/kg PCC: aPTT +11 s; +90 μg rFVIIa: CT -141 s; +25 IU/kg aPCC: CT -142 s, aPTT -9 s, PT ratio +14%, PT -10.5 s; +50 IU/kg aPCC: CT -118 s, aPTT -7 s, PT ratio +17%, PT -12.2 s. DISCUSSION: rFVIIa and aPCC, but not PCC, appear to shorten coagulation times significantly in standard laboratory and thromboelastometry assays. These results need confirmation through evaluation of these agents in the clinical setting.
Authors: Lynne Anderson; Isma Quasim; Mark Steven; Stephen F Moise; Ben Shelley; Stefan Schraag; Andrew Sinclair Journal: J Cardiothorac Vasc Anesth Date: 2014-09-26 Impact factor: 2.628
Authors: Anne Godier; Anastasia Miclot; Bernard Le Bonniec; Marion Durand; Anne-Marie Fischer; Joseph Emmerich; Catherine Marchand-Leroux; Thomas Lecompte; Charles-Marc Samama Journal: Anesthesiology Date: 2012-01 Impact factor: 7.892
Authors: Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing Journal: Clin Pharmacol Ther Date: 2005-10 Impact factor: 6.875
Authors: Edelgard Lindhoff-Last; Meyer Michel Samama; Thomas L Ortel; Jeffrey I Weitz; Theodore E Spiro Journal: Ther Drug Monit Date: 2010-12 Impact factor: 3.681
Authors: Veronica Yank; C Vaughan Tuohy; Aaron C Logan; Dena M Bravata; Kristan Staudenmayer; Robin Eisenhut; Vandana Sundaram; Donal McMahon; Ingram Olkin; Kathryn M McDonald; Douglas K Owens; Randall S Stafford Journal: Ann Intern Med Date: 2011-04-19 Impact factor: 25.391
Authors: Ritvij Bowry; Stuart Fraser; Joancy M Archeval-Lao; Stephanie A Parker; Chunyan Cai; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2014-01-14 Impact factor: 7.914
Authors: Sean van Diepen; Anne S Hellkamp; Manesh R Patel; Richard C Becker; Günter Breithardt; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Christopher C Nessel; Daniel E Singer; Scott D Berkowitz; Robert M Califf; Keith A A Fox; Kenneth W Mahaffey Journal: Circ Heart Fail Date: 2013-05-30 Impact factor: 8.790